Unit Dose Manufacturing Market Report 2026

The unit dose manufacturing market size has grown exponentially in recent years. It will grow from $39.37 billion in 2025 to $47.78 billion in 2026 at a compound annual growth rate (CAGR) of 21.4%. The growth in the historic period can be attributed to rise of hospital and pharmacy demand, increased prevalence of chronic diseases, adoption of standardized dosing formats, improvements in packaging technology, cost-efficiency in bulk drug manufacturing.

The unit dose manufacturing market size is expected to see exponential growth in the next few years. It will grow to $106.79 billion in 2030 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to growth in personalized medicine, increased outsourcing of unit dose manufacturing, expansion of home healthcare services, rising regulatory focus on medication safety, innovations in sustainable and biodegradable packaging. Major trends in the forecast period include personalized dosage packaging, automation in drug filling and packaging, smart inventory management, regulatory compliance and serialization, eco-friendly packaging solutions.

The rising healthcare expenditure is expected to drive the growth of the unit dose manufacturing market in the coming years. Healthcare spending includes costs related to medical services, family planning, nutrition programs, and emergency health assistance. Increased expenditure supports the development and expansion of healthcare services, including unit dose manufacturing, which in turn fuels market growth. For example, in September 2024, Cross River Therapy, a US-based provider of ABA therapy services, reported that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicines, and projected spending expected to reach $605-$635 billion by 2025. Consequently, the rise in healthcare spending is contributing to the expansion of the unit dose manufacturing market.

Leading companies in the unit dose manufacturing market are focusing on strategic partnerships to strengthen their market positions. Strategic partnerships involve leveraging complementary strengths and resources to achieve mutual benefits. For instance, in November 2023, iA, a US-based provider of integrated pharmacy fulfillment platforms, announced a distributor agreement with Euclid Medical Products, a US-based specialist in multi-unit automated packaging and barcoding systems. Through this partnership, iA’s NEXiA Enterprise Software Suite integrates Euclid’s Axial Adherence Packaging Technology into centralized fulfillment solutions, expanding capabilities for multiple medication dispensing methods, including both multi- and unit-dose automated packaging.

In February 2025, Jabil Inc., a US-based manufacturing company, acquired Pharmaceutics International, Inc. (Pii) for $307 million. The acquisition enables Jabil to expand its pharmaceutical solutions business by integrating development and manufacturing services, offering end-to-end drug development, clinical, and commercial production capabilities. Pii is a US-based contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.

Major companies operating in the unit dose manufacturing market are Nipro Corporation, Catalent Inc., Corden Pharma GmbH, LTS Lohmann Therapie-Systeme AG, PCI Pharma Services, Comar LLC, Renaissance Lakewood LLC, Mikart LLC, Tapemark Company Inc., Bilcare Research, Medical Packaging Inc, American Health Packaging, Aphena Pharma Solutions, Vetter Pharma International GmbH, Baxter International Inc., Fresenius Kabi AG, Patheon Inc., Recipharm AB, Lonza Group AG, Aenova Group, Piramal Pharma Solutions, Jubilant HollisterStier Inc., IDT Biologika GmbH, Famar HealthCare, Vion Pharmaceuticals.

North America was the largest region in the unit dose manufacturing market in 2025. The regions covered in the unit dose manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the unit dose manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the unit dose manufacturing market by increasing the cost of imported raw materials, specialized packaging components, and machinery used in production. This has particularly impacted regions like Asia-Pacific and North America where manufacturing and sourcing are highly globalized. Segments such as liquid vials, pre-filled syringes, and transdermal patches face higher production costs, while solid unit dose products are moderately affected. Positive impacts include encouraging local manufacturing and investments in automation to reduce reliance on imported components, fostering innovation and efficiency in production.

The unit dose manufacturing market research report is one of a series of new reports that provides unit dose manufacturing market statistics, including unit dose manufacturing industry global market size, regional shares, competitors with a unit dose manufacturing market share, detailed unit dose manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the unit dose manufacturing industry. This unit dose manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Unit dosage manufacturing involves producing individual, pre-packaged doses of drugs or other products containing a specific amount intended for single-dose use. These are typically provided in convenient forms such as tablets, capsules, or vials for easy patient administration.

The main products in unit dose manufacturing include liquid unit doses, solid unit doses, and others. A liquid unit dose is a precise, pre-measured amount of liquid medication or chemical packaged for single-use administration. These products are sourced through in-house production or outsourcing and are used by independent pharmacies, long-term care facilities, hospitals, and other healthcare providers.

The unit dose manufacturing market consists of sales of sachets, small bottles, tubes, and pods. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.